暂无推荐供应商。我要出现这里
化源商城直购
[1]. Ho MY, et al. Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers. Xenobiotica. 2014 Apr;44(4):352-68.